TAZ suppresses NFAT5 activity through tyrosine phosphorylation

Molecular and Cellular Biology

Volumn 32, Issue 24, 2012, Pages 4925-4932

  Jang, Eun Jung ^a   Jeong, Hana ^a   Han, Ki Hwan ^b   Kwon, Hyug Moo ^c   Hong, Jeong Ho ^d   Hwang, Eun Sook ^a  

^a Ewha Womans University   (South Korea)

^b Ewha Womans University School of Medicine   (South Korea)

^c Ulsan National Institute of Science and Technology   (South Korea)

^d Korea University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; DNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFAT5; TRANSCRIPTIONAL COACTIVATOR WITH PDZ BINDING MOTIF PROTEIN; TYROSINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; DNA BINDING; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HYPEROSMOTIC STRESS; KIDNEY CELL; MOUSE; NONHUMAN; OSMOREGULATION; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION INITIATION; WILD TYPE;

ANIMALS; BASE SEQUENCE; CELL LINE; CERCOPITHECUS AETHIOPS; COS CELLS; DNA; HEK293 CELLS; HUMANS; KIDNEY; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUTANT PROTEINS; OSMOTIC PRESSURE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-ABL; RECOMBINANT PROTEINS; TRANSCRIPTION FACTORS; TYROSINE;

EID: 84871860525     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00392-12     Document Type: Article

References (37)

1. Berl T, Siriwardana G, Ao L, Butterfield LM, Heasley LE. 1997. Multiple mitogen-activated protein kinases are regulated by hyperosmolality in mouse IMCD cells. Am. J. Physiol. 272:F305-F311.
2. Burg MB, Ferraris JD, Dmitrieva NI. 2007. Cellular response to hyperosmotic stresses. Physiol. Rev. 87:1441-1474.
3. Cha JH, et al. 2001. Hydration status affects nuclear distribution of transcription factor tonicity responsive enhancer binding protein in rat kidney. J. Am. Soc. Nephrol. 12:2221-2230.
4. Chan SW, et al. 2008. A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res. 68:2592-2598.
5. Chan SW, et al. 2009. TEADs mediate nuclear retention of TAZ to promote oncogenic transformation. J. Biol. Chem. 284:14347-14358.
6. Cui CB, Cooper LF, Yang X, Karsenty G, Aukhil I. 2003. Transcriptional coactivation of bone-specific transcription factor Cbfa1 by TAZ. Mol. Cell. Biol. 23:1004-1013.
7. Di Palma T, et al. 2009. TAZ is a coactivator for Pax8 and TTF-1, two transcription factors involved in thyroid differentiation. Exp. Cell Res. 315:162-175.
8. Duning K, et al. 2010. Polycystin-2 activity is controlled by transcriptional coactivator with PDZ binding motif and PALS1-associated tight junction protein. J. Biol. Chem. 285:33584-33588.
9. Ferraris JD, Persaud P, Williams CK, Chen Y, Burg MB. 2002. cAMPindependent role of PKA in tonicity-induced transactivation of tonicityresponsive enhancer/osmotic response element-binding protein. Proc. Natl. Acad. Sci. U. S. A. 99:16800-16805.
10. Ferraris JD, et al. 1996. ORE, a eukaryotic minimal essential osmotic response element. The aldose reductase gene in hyperosmotic stress. J. Biol. Chem. 271:18318-18321.
11. Gallazzini M, Yu MJ, Gunaratne R, Burg MB, Ferraris JD. 2010. c-Abl mediates high NaCl-induced phosphorylation and activation of the transcription factor TonEBP/OREBP. FASEB J. 24:4325- 4335.
12. Halterman JA, Kwon HM, Wamhoff BR. 2012. Tonicity-independent regulation of the osmosensitive transcription factor TonEBP (NFAT5). Am. J. Physiol. Cell Physiol. 302:C1-C8.
13. Hong JH, et al. 2005. TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science 309:1074-1078.
14. Hossain Z, et al. 2007. Glomerulocystic kidney disease in mice with a targeted inactivation of Wwtr1. Proc. Natl. Acad. Sci. U. S. A. 104:1631- 1636.
15. Jeong H, et al. 2010. TAZ as a novel enhancer of MyoD-mediated myogenic differentiation. FASEB J. 24:3310-3320.
16. Kanai F, et al. 2000. TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. EMBO J. 19:6778- 6791.
17. Kang HS, Beak JY, Kim YS, Herbert R, Jetten AM. 2009. Glis3 is associated with primary cilia and Wwtr1/TAZ and implicated in polycystic kidney disease. Mol. Cell. Biol. 29:2556-2569.
18. Kojima R, et al. 2010. Hypertonicity-induced expression of monocyte chemoattractant protein-1 through a novel cis-acting element and MAPK signaling pathways. J. Immunol. 184:5253-5262.
19. Lei QY, et al. 2008. TAZ promotes cell proliferation and epithelialmesenchymal transition and is inhibited by the hippo pathway. Mol. Cell. Biol. 28:2426-2436.
20. Liu CY, et al. 2010. The hippo tumor pathway promotes TAZ degradation by phosphorylating a phosphodegron and recruiting the SCFbeta-TrCP E3 ligase. J. Biol. Chem. 285:37159-37169.
21. Lopez-Rodriguez C, et al. 2004. Loss of NFAT5 results in renal atrophy and lack of tonicity-responsive gene expression. Proc. Natl. Acad. Sci. U. S. A. 101:2392-2397.
22. Mahoney WM, Jr, Hong JH, Yaffe MB, Farrance IK. 2005. The transcriptional co-activator TAZ interacts differentially with transcriptional enhancer factor-1 (TEF-1) family members. Biochem. J. 388:217-225.
23. Mak MC, et al. 2011. Embryonic lethality in mice lacking the nuclear factor of activated T cells 5 protein due to impaired cardiac development and function. PLoS One 6:e19186. doi:10.1371/journal.pone.0019186.
24. Makita R, et al. 2008. Multiple renal cysts, urinary concentration defects, and pulmonary emphysematous changes in mice lacking TAZ. Am. J. Physiol. Renal Physiol. 294:F542-F553.
25. Miah SM, et al. 2004. Activation of Syk protein tyrosine kinase in response to osmotic stress requires interaction with p21-activated protein kinase Pak2/gamma-PAK. Mol. Cell. Biol. 24:71- 83.
26. Miyakawa H, et al. 1998. Cis- and trans-acting factors regulating transcription of the BGT1 gene in response to hypertonicity. Am. J. Physiol. 274:F753-F761.
27. Miyakawa H, Woo SK, Dahl SC, Handler JS, Kwon HM. 1999. Tonicityresponsive enhancer binding protein, a rel-like protein that stimulates transcription in response to hypertonicity. Proc. Natl. Acad. Sci. U. S. A. 96:2538-2542.
28. Murakami M, Nakagawa M, Olson EN, Nakagawa O. 2005. A WW domain protein TAZ is a critical coactivator for TBX5, a transcription factor implicated in Holt-Oram syndrome. Proc. Natl. Acad. Sci. U. S. A. 102:18034-18039.
29. Murakami M, et al. 2006. Transcriptional activity of Pax3 is co-activated by TAZ. Biochem. Biophys. Res. Commun. 339:533-539.
30. Park KS, et al. 2004. TAZ interacts with TTF-1 and regulates expression of surfactant protein-C. J. Biol. Chem. 279:17384-17390.
31. Reinehr R, Becker S, Hongen A, Haussinger D. 2004. The Src family kinase Yes triggers hyperosmotic activation of the epidermal growth factor receptor and CD95. J. Biol. Chem. 279:23977-23987.
32. Roth I, et al. 2010. Osmoprotective transcription factor NFAT5/TonEBP modulates nuclear factor-kappaB activity. Mol. Biol. Cell 21:3459-3474.
33. Tian Y, et al. 2007. TAZ promotes PC2 degradation through an SCFbeta- Trcp E3 ligase complex. Mol. Cell. Biol. 27:6383- 6395.
34. Uchida S, et al. 1993. Molecular cloning of the cDNA for an MDCK cell Na(+)- and Cl(-)-dependent taurine transporter that is regulated by hypertonicity. Proc. Natl. Acad. Sci. U. S. A. 90:7424.
35. Yamauchi A, et al. 1992. Cloning of a Na(+)- and Cl(-)-dependent betaine transporter that is regulated by hypertonicity. J. Biol. Chem. 267: 649-652.
36. Yamauchi A, Uchida S, Preston AS, Kwon HM, Handler JS. 1993. Hypertonicity stimulates transcription of gene for Na(+)-myo-inositol cotransporter in MDCK cells. Am. J. Physiol. 264:F20-F23.
37. Zhang H, et al. 2009. TEAD transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition. J. Biol. Chem. 284:13355-13362.